Status:
COMPLETED
Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India
Lead Sponsor:
AstraZeneca
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18-130 years
Brief Summary
This is a non-interventional, cross-sectional, multicentre, observational study planned to be conducted at 15 sites across all geographical regions of India. The study targets to enrol 240 patients wi...
Detailed Description
This is a non-interventional, cross-sectional, multicentre, observational study to be conducted at 15 sites from different geographical regions across India. The study targets to enrol 240 patients wi...
Eligibility Criteria
Inclusion
- Patients who provide written informed consent
- Female ≥ 18 years of age
- Previously or newly diagnosed ovarian, primary peritoneal, or fallopian tube cancer patients.
Exclusion
- 1\. Patient with any medical condition that, in the opinion of the investigator, would interfere with safe completion of the study
Key Trial Info
Start Date :
March 22 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 21 2018
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT03471572
Start Date
March 22 2018
End Date
December 21 2018
Last Update
December 18 2019
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Bangalore, Karnataka, India, 560027
2
Research Site
Mumbai, Maharashtra, India, 400012
3
Research Site
Mumbai, Maharashtra, India, 400071
4
Research Site
Delhi, New Delhi, India, 110005